

ARAMIS LAB BRAIN DATA SCIENCE



a science pour la sante _____ From science to health



Temporal dynamics of the Scale for the Assessment and Rating of Ataxia in autosomal dominant cerebellar ataxias.

Authors: Paul Moulaire¹, Pierre Emmanuel Poulet², Emilien Petit², Thomas Klockgether³, Alexandra Durr², Tetsuo Ashisawa⁴, Sophie Tezenas du Montcel², for the READISCA consortium

Author affiliations:

1.Sorbonne Université, Paris Brain Institute, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, INRIA, CNRS, APHP, Paris, France.

2. Sorbonne Université, Paris Brain Institute, INSERM, INRIA, CNRS, APHP, 75013 Paris, France.

3.German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany.

4. Weill Cornell Medicine at The Houston Methodist Research Institute, Houston, TX 77030, USA.

SARA scale, context & aims of the study

SARA (Scale for the Assessment and Rating of Ataxia):

- -Clinical score (from 0 to 40)
- -Assess the presence and severity of Ataxia

Context:

-Upcoming treatments (reliable outcome needed)

Aims:

- -Assess the temporal dynamics of SARA:
 - At the item level
 - Globally


ltem 1-Ga	it (max 8)
ltem 2-St	ance (max 6)
Item 3-Sit	ting (max 4)
ltem 4-Sp	eech (max 6)
ltem 5-Fir	nger Chase (max 4)
ltem 6-Fir	nger Nose (max 4)
ltem 7-Ha	nd Fast (max 4)
ltem 8-He	el Shin (max 4)




Methods



Disease distribution at baseline



Parameters and comparisons



Participants:

- -Grouping of 4 cohorts (EUROSCA, RISCA, CRC-SCA, SPATAX)
- -1210 participants (SCA1, SCA2, SCA3, SCA6)
- -4092 visits
- -3697 patients-years


Statistical tool:

-Bayesian mixed effect model, (Leaspy)

Average trajectory: Time spent at each level

Results, Item level analysis






-Different speed of progression.


-Non linear progression

A: Average time for a one-point increase



Results: Global progression of the scale






-Linear progression of SARA scale

-Best overlap between score 4 and 36

Results: Required sample size for therapeuthic trials

Inclusion criterion SARA between 4 and 36

=> Less participants required to highline the same treatment effect in a trial



 α =5%, β =90%, treatment effect=50%, duration=12 mois



Conclusion



New findings:

- -Heterogeneous progression at the item level
- -Stable and linear temporal dynamic of the SARA scale
- -Better properties between SARA score 4 and 36

More informations available:

RESEARCH ARTICLE

Temporal Dynamics of the Scale for the Assessment and Rating of Ataxia in Spinocerebellar Ataxias

Paul Moulaire, MSc,¹ Pierre Emmanuel Poulet, MSc,² Emilien Petit, MSc,² Thomas Klockgether, MD,³ Alexandra Durr, MD, PhD,² Tetsuo Ashisawa, MD,⁴ Sophie Tezenas du Montcel, MD, PhD,^{2*} and for the READISCA Consortium





Acknowledgements

Sophie Tezenas du Montcel

Thomas Klockgether

Alexandra Durr

Tetsuo Ashisawa

Pierre Emmanuel Poulet

Emilien Petit









Temporal dynamic as a function of cofactors


ARAMIS LAB BRAIN DATA SCIENCE

Temporal dynamics as a function of SCA type Individual parameters: Acceleration factor (Xi) Age of start of progression (Tau) 1.1 -Confirmatory results: **Different dynamics between SCAs** Acceleration factor (Xi) 0 0.9 35 40 45 50 Age of start of progression (Tau)

SCA1 SCA2 SCA3 SCA6

Temporal dynamic as a function of continent (A) and cohort (B)





Temporal dynamic as a gender



